Insilico Medicine, a clinical-stage generative artificial intelligence-driven drug discovery company, has announced a new research and licensing collaboration with Eli Lilly, a global leader in pharmaceutical innovation. The partnership will combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in drug development and disease biology to jointly identify and advance novel therapies. Under the agreement, Insilico will leverage its validated Pharma.AI platform and extensive drug discovery capabilities to generate, design, and optimize candidate compounds targeting specific disease pathways defined by the collaboration. Insilico is eligible to receive over $100 million in total, including an upfront payment, milestone-based payments tied to development progress, and tiered royalties on net sales if any resulting therapies reach the market. “We are delighted to expand our partnership with Lilly, a company with a long-standing commitment to medical breakthroughs and patient impact,” said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. “Lilly has been a valued user of our Pharma.AI software suite, and this new collaboration further underscores the growing recognition of our AI-driven approach to drug discovery. By combining our technologies with Lilly’s world-class development capabilities, we are accelerating the path to transformative treatments for patients in need.” This collaboration marks a significant evolution of a relationship that began in 2023 with a software licensing agreement. Since then, Insilico has demonstrated the power of its AI and automation systems in drastically shortening the preclinical drug discovery timeline. While traditional early-stage drug discovery can take three to six years, Insilico has nominated 20 preclinical candidates between 2021 and 2024, achieving an average turnaround of just 12 to 18 months from project initiation to preclinical candidate nomination. Each program involved testing only 60 to 200 molecules, a fraction of the traditional screening scale. Insilico Medicine is a global biotech company at the forefront of AI in life sciences, using its proprietary Pharma.AI platform and fully automated laboratory to drive innovation across multiple therapeutic areas, including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. The company is also expanding the application of its AI technologies into advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, visit www.insilico.com.